Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) released its earnings results on Wednesday. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.02, Bloomberg Earnings reports. The company had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.30 EPS. Sucampo Pharmaceuticals updated its FY17 guidance to $1.10-1.15 EPS.

SCMP has been the subject of several analyst reports. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. UBS AG reduced their target price on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, October 12th. Mizuho lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $14.00 to $12.00 in a report on Tuesday, October 3rd. TheStreet lowered shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Finally, Maxim Group set a $23.00 target price on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Sucampo Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $16.50.

ILLEGAL ACTIVITY NOTICE: “Sucampo Pharmaceuticals, Inc. (SCMP) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/11/02/sucampo-pharmaceuticals-inc-scmp-issues-quarterly-earnings-results-beats-expectations-by-0-02-eps.html.

In other Sucampo Pharmaceuticals news, insider Jason Patrick Meyenburg bought 4,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Wednesday, September 6th. The stock was acquired at an average cost of $12.13 per share, with a total value of $48,520.00. Following the purchase, the insider now directly owns 30,228 shares in the company, valued at approximately $366,665.64. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Jones W. Bryan bought 4,700 shares of Sucampo Pharmaceuticals stock in a transaction dated Friday, August 4th. The shares were acquired at an average cost of $10.60 per share, with a total value of $49,820.00. Following the completion of the purchase, the insider now owns 4,700 shares in the company, valued at $49,820. The disclosure for this purchase can be found here. Corporate insiders own 4.13% of the company’s stock.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Earnings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.